109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
Muscle targeting complexes and uses thereof for treating dystrophinopathies
#602Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#603THERAPEUTIC USES AND METHODS
#604Nucleic Acids and Methods for the Treatment of Pompe Disease
#605TREATMENT OF MST1R RELATED DISEASES AND DISORDERS
#606RNA THERAPEUTICS AND METHODS OF USE THEREOF
#607Treatment of MST1 related diseases and disorders
#608TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#609IRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
#610COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION
#611RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use
#612STAUFEN1 REGULATING AGENTS AND ASSOCIATED METHODS
#613NKD2 AS TARGET FOR TREATING RENAL FIBROSIS
#614HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE
#615ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM
#616NUCLEIC ACID MOLECULE AND ITS USE
#617MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#618LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF
#619Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment
#620ANTISENSE OLIGONUCLEOTIDES FOR MODULATING TMEM106B EXPRESSION
#621ANTISENSE COMPOUND FOR MODULATING WFDC2 EXPRESSION
#622COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
#623TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS
#624USE OF SPLICE SWITCHING OLIGONUCLEOTIDES FOR EXON SKIPPING-MEDIATED KNOCKDOWN OF PIM2
#625OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURES
#626NOVEL COMPOUND AND APPLICATION THEREOF
#627PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR
#628Antisense Nucleic Acids
#629DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#630Selective Antisense Compounds and Uses Thereof
#631OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51
#632Targeting GPR65 for the Treatment of Cancer in Overweight and Obese Individuals
#633GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS
#634DENDRITIC CONJUGATES FOR THE LUNG DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#635METHODS FOR THE TREATMENT OF OCULAR ROSACEA
#636SELECTIVE INHIBITORS OF ROCK2 FOR THE TREATMENT OF MUSCULAR DYSTROPHY
#637Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
#638EXTRA-HEPATIC DELIVERY IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#639RENAL INJURY BIOMARKERS AS BIOMARKERS FOR ACUTE HEPATIC PORPHYRIA (AHP)
#640Compounds and methods for reducing LRRK2 expression
#641METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#642MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#643ANTISENSE OLIGONUCLEOTIDE THERAPY FOR H3.3 K27M DIFFUSE MIDLINE GLIOMAS
#644COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
#645LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#646COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE
#647DENDRITIC CONJUGATES FOR THE BRAIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#648COMPOSITIONS AND METHODS FOR INTRACELLULAR THERAPEUTICS
#649NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#650CONJUGATE
#651RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION
#652Compositions and methods for modulating apolipoprotein (a) expression
#653COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#654PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASE
#655TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS
#656DENDRITIC CONJUGATES FOR THE SKIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#657TREATMENT FOR TYROSINE DEGRADATION-ASSOCIATED DISORDERS
#658EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
#659BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#660METHOD
#661METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING COMPLEMENT ALTERNATIVE PATHWAY INHIBITORS
#662NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
#663Compositions and Methods for Treatment and Prevention of Misfolded Proteins
#664USE OF OLIGONUCLEOTIDES FOR INDIVIDUALS WITH RENAL IMPAIRMENT
#665THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
#666RNA EDITING
#667COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF TMIGD2
#668MODIFIED PRODUCER CELLS FOR EXTRACELLULAR VESICLE PRODUCTION
#669PRODUCTS AND METHODS FOR PROMOTING MYOGENESIS
#670ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#671OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
#672LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE
#673COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY
#674STRUCTURE-BASED DESIGN OF ANTISENSE OLIGONUCLEOTIDE DRUGS
#675TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
#676LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS
#677RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF DUX4
#678MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
#679Antisense oligonucleotide targeting ATN1 mRNA or pre-mRNA
#680ANTISENSE OLIGONUCLEOTIDES TARGETING ACTL6B
#681MORPHOLINO OLIGOMERS FOR TREATMENT OF PERIPHERAL MYELIN PROTEIN 22 RELATED DISEASES
#682MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#683Compositions and Methods for Silencing MYOC Expression
#684PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF PERIPHERAL MYELIN PROTEIN-22
#685COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS
#686NEPHROTOXICITY REDUCING AGENT
#687Selective Reduction of Allelic Variants
#688TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#689COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#690METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY
#691SMALL INTERFERING RNA TARGETING APOC3 AND USES THEREOF
#692CTLA-4 APTAMER CONJUGATES
#693REDUCING INTRON RETENTION
#694POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF
#695COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT'S DISEASE AND/OR RETINAL BINDING PROTEIN 4 (RBP4)-ASSOCIATED DISORDERS
#696COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION
#697METHODS AND COMPOSITIONS TO DIAGNOSE AND TREAT TAUOPATHIES UTILIZING TRANSCRIPT VARIANTS OF PSEN2
#698LIPID NANOPARTICLE SPHERICAL NUCLEIC ACIDS
#699MODULATING TRANSCRIPTIONAL CONDENSATES
#700LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
#701METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#702Inhibition of Diacylglycerol Kinase to Augment Adoptive T cell Transfer
#703COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#704COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#705SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF
#706iRNA Compositions and Methods for Silencing Filamin A (FLNA)
#707METHODS AND COMPOSITIONS FOR TREATING CHRONIC LIVER DISEASE AND HEPATOCELLULAR CARCINOMA
#708Combination of Antisense Oligomers
#709COMPOUNDS FOR MODULATING UNC13A EXPRESSION
#710COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION
#711COMPOSITION COMPRISING MIR 145 INHIBITOR AS ACTIVE INGREDIENT FOR TREATMENT OF MYOCARDIAL INFARCTION
#712CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE
#713METHODS OF PLACING LOCKED NUCLEIC ACIDS IN SMALL INTERFERING RNA STRANDS
#714METHOD FOR IMPROVING GENETIC ENGINEERING OF ADOPTIVE CELL THERAPIES
#715ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION
#716Selective Antisense Compounds and Uses Thereof
#717ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES
#718MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE
#719MODULATION OF NOX4 EXPRESSION
#720SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF
#721Oligonucleotides for Modulating Apolipoprotein E4 Expression
#722ATXN2 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING ATXN2-ASSOCIATED NEURODEGENERATIVE DISEASES
#723ANTISENSE OLIGONUCLEOTIDES FOR INCREASING SHANK3 EXPRESSION
#724Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy
#725CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#726BRANCHED OLIGONUCLEOTIDES
#727NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES
#728COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC OLIGONUCLEOTIDES TO THE CENTRAL NERVOUS SYSTEM
#729TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#730COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#731Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides
#732METHOD FOR SYNTHESIS OF LINKAGE MODIFIED OLIGOMERIC COMPOUNDS
#733OLIGONUCLEOTIDES FOR IFN-GAMMA SIGNALING PATHWAY MODULATION
#734Compounds and Methods for Modulating Splicing of Pre-MRNA
#735LIPID CONJUGATION FOR TARGETING NEURONS OF THE CENTRAL NERVOUS SYSTEM
#736Antisense Oligomer
#737OLIGONUCLEOTIDES
#738COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#739COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#740PRECIPITATION SUPPRESSING AGENT
#741METHODS FOR PRODUCTION AND QUANTIFICATION OF UNIQUE MOLECULAR IDENTIFIER-LABELED BEADS
#742METHODS OF TREATING ALZHEIMER'S DISEASE
#743Conjugated antisense compounds and their use
#744Engineered Guide RNAs and Polynucleotides
#745LIGAND-BINDING NUCLEIC ACID COMPLEX
#746CD71 BINDING FIBRONECTIN TYPE III DOMAINS
#747METHODS AND COMPOSITIONS FOR MODULATING STING SIGNALING AND INNATE IMMUNE RESPONSES
#748COMPOSITION COMPRISING AN RNA THERAPEUTIC TARGETING FAT10 AND USES OF SAME FOR TREATING DISORDERS CHARACTERIZED BY ABNORMAL LIPID ACCUMULATION
#749OLIGONUCLEOTIDES AND COMPOSITIONS THEREOF FOR NEUROMUSCULAR DISORDERS
#750Chemically modified single-stranded rna-editing oligonucleotides
#751TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER
#752SMALL COMPLEMENTARY NUCLEIC ACIDS, COMPOSITIONS CONTAINING THE SAME, AND METHODS FOR USE AS ANTIVIRALS
#753METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
#754COMPOSITION FOR TREATING METASTATIC SOLID CANCER, COMPRISING TSG6 INHIBITOR
#755METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE
#756TIM-3 MODULATES ANTI-TUMOR IMMUNITY BY REGULATING INFLAMMASOME ACTIVATION
#757MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS
#758MODULATION OF COASY EXPRESSION
#759ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES
#760SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR 6 (STAT6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#761METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
#762EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6
#763ANTISENSE OLIGONUCLEOTIDE TARGETING CAV3.1 GENE AND USES THEREOF
#764Modulators of Complement Factor B
#765Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors
#766NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS
#767METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY
#768CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#769COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
#770OLIGONUCLEOTIDE AND TARGET RNA SITE-SPECIFIC EDITING METHOD
#771IONIZABLE LIPID COMPOUNDS
#772METHODS OF USING USP15 INHIBITORS
#773COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS
#774COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY
#775ANTISENSE OLIGONUCLEOTIDES TARGETING ADENOSINE KINASE
#776SIRNA TARGETING TMPRSS6 FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
#777COMB SHAPED ANTIVIRALS ENDING WITH OR WITHOUT CHAIN TERMINATING BASES
#778Heteronucleic acid containing scpBNA or AmNA
#779PREVENTION OR TREATMENT OF MYOPATHY USING MIR-33B INHIBITOR
#780POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS
#781Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#782COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
#783Viral Vectors For Treating Neurogenic Detrusor Overactivity
#784COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION
#785SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE
#786NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN
#787CHIRAL CONTROL
#788VON WILLEBRAND FACTOR (VWF) INHIBITORS
#789COMPOSITION FOR TREATING OSTEOARTHRITIS
#790COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#791FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE
#792OPTIMIZED 2'- MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE
#793REPROGRAMMING OF NON-NEURONAL CELLS INTO NEURONS AND METHODS AND COMPOSITIONS TO TREAT NEURODEGENERATIVE DISEASES AND DISORDERS
#794MODULATING APOLIPOPROTEIN (A) EXPRESSION
#795SMALL ACTIVATING RNA INCREASING SHANK EXPRESSION AND METHOD OF TREATING INTELLECTUAL DISABILITIES AND ASSOCIATED COMORBIDITIES ASSOCIATED WITH SHANK HAPLOINSUFFICIENCY
#796MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA
#797COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#798TREATMENT OF NEUROLOGICAL DISORDERS
#799THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS
#800Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons
#801ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#802PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#803COMPOSITIONS AND METHODS FOR TREATING CANCER
#804METHODS OF MODULATING ALK
#805EXTRACELLULAR VESICLE COMPOSITIONS
#806INHIBITORY NUCLEIC ACIDS FOR FACTOR H FAMILY PROTEINS
#807HIGH EFFICIENCY TRANS-SPLICING FOR REPLACEMENT OF TARGETED RNA SEQUENCES IN HUMAN CELLS
#808COMPOUNDS AND METHODS FOR MODULATING PLP1
#809Linear DNA with Enhanced Resistance Against Exonucleases
#810PRODUCTS AND METHODS FOR INDUCING EXON 2 SKIPPING OF THE DMD GENE IN TREATING MUSCULAR DYSTROPHY
#811COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#812REDIRECTING RISC FOR RNA EDITING
#813PHARMACEUTICAL COMPOSITION CONTAINING CELL-DERIVED NATURAL OR ARTIFICIAL NANOVESICLES LOADED WITH ANTISENSE OLIGONUCLEOTIDE-BASED DRUG
#814ORAL DELIVERY OF OLIGONUCLEOTIDES
#815COMPOSITION FOR DIAGNOSIS OR TREATMENT OF ANTICANCER DRUG RESISTANCE
#816NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE
#817Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
#818METHOD AND COMPOSITIONS FOR PREVENTING TUMOR DEVELOPMENT AND METASTASIS
#819FUNCTIONAL NUCLEIC ACID MOLECULES DIRECTED TO TARGETS FOR NERVOUS SYSTEM DISORDERS
#820RNAi-NANOPARTICLE CONJUGATE, COMPOSITION, AND METHOD OF SYNTHESIS THEREOF
#821Compositions for Modulating C9ORF72 Expression
#822PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY
#823METHODS OF TREATING DUCHENNE MUSCULAR DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
#824TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
#825Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#826Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
#827COMPOUNDS AND METHODS FOR REDUCING NLRP3 EXPRESSION
#828SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES
#829CONJUGATES OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES (SIRNASO) AND METHODS OF USE IN GENE SILENCING
#830RNA SILENCING AGENTS AND METHODS OF USE
#831ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF NEUROLOGICAL DISORDERS
#832NOVEL PEPTIDE-OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF
#833METHODS OF TREATING MYOTONIC DYSTROPHY TYPE 1 USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
#834COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
#835Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
#836TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
#837METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
#838SHORT MULTI-REPEAT RNA TARGETING GENE SILENCING
#839ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION
#840COMPOSITIONS AND METHODS FOR MODULATING SOS GENE EXPRESSIONS
#841MICRORNA-27B INHIBITORS
#842CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE
#843VECTORS
#844TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
#845SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF
#846ANTISENSE OLIGONUCLEOTIDES THAT BIND TO EXON 51 OF HUMAN DYSTROPHIN PRE-MRNA
#847DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES
#848METHODS FOR MODULATING FMR1 EXPRESSION
#849OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#850RELIABLE IDENTIFICATION OF REGIONS ('A SITES') IN COMPLEX RNA MOLECULES THAT ARE ACCESSIBLE TO NUCLEIC ACIDS OR COMPLEXES OF NUCLEIC ACIDS WITH ENDONUCLEASES
#851COMPOSITIONS AND METHODS FOR ENHANCING BIOMASS PRODUCTIVITY IN PLANTS
#852ANTISENSE OLIGONUCLEOTIDE
#853EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST
#854METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS
#855NUCLEIC ACID DELIVERY TO THE CENTRAL NERVOUS SYSTEM
#856METHODS OF TREATING OSMIDROSIS
#857PHARMACEUTICAL USE OF FAM19A5 INVOLVED IN REGULATING GLIOGENESIS
#858Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA)
#859ANTISENSE OLIGONUCLEOTIDES FOR THEIR USE IN AN ANTI-CANCER TREATMENT
#860Treatment Of Kidney Diseases With A Combination of Angiopoietin Like 3 (ANGPTL3) Inhibitors And Solute Carrier Family 5 Member 2 (SLC5A2) Inhibitors
#861Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy
#862CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#863Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
#864THERAPEUTIC SPLICE-SWITCHING OLIGONUCLEOTIDES FOR CANCER
#865ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#866Splicing Modulators for the Treatment of Timothy Syndrome
#867ANTISENSE OLIGONUCLEOTIDES TARGETING FOXG1
#868GUIDE RNA FOR EDITING POLYADENYLATION SIGNAL SEQUENCE OF TARGET RNA
#869TREATING DISORDERS ASSOCIATED WITH DYRK1A DYSFUNCTION
#870Compositions and methods for organ specific delivery of nucleic acids
#871MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA
#872MODULATION OF GYS1 EXPRESSION
#873USING siRNAs AGAINST TAU CIRCULAR RNAS AS A RATIONAL THERAPY FOR ALZHEIMER'S DISEASE
#874CD70-TARGETED MICELLES ENHANCE HIF2? siRNA DELIVERY AND INHIBIT ONCOGENIC FUNCTIONS IN PATIENT-DERIVED CLEAR CELL RENAL CARCINOMA CELLS
#875Selective Antisense Compounds and Uses Thereof
#876ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF CORNEAL DYSTROPHIES
#877Oligonucleotide Comprising Inosine for Treating DMD
#878TARGETED RNA EDITING
#879MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
#880METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS
#881Viral Vectors For Treating Neurogenic Detrusor Overactivity
#882NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN
#883OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
#884COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#885MODULATION OF TRANSTHYRETIN EXPRESSION
#886COMPOSITIONS FOR USE IN THE TREATMENT OF CHD2 HAPLOINSUFFICIENCY AND METHODS OF IDENTIFYING SAME
#887C/EBP Alpha Short Activating RNA Compositions and Methods of Use
#888METHODS AND KITS FOR DETECTING A RISK FOR DEVELOPING NEUROLOGICAL OR NEUROPHYSIOLOGICAL DISORDERS
#889MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#890iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)
#891COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#892OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#893MODIFIED HETERO NUCLEIC ACIDS
#894METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF
#895Methods for Treatment of Alport Syndrome
#896COMPOSITIONS AND METHODS FOR TREATING PULMONARY ARTERIAL HYPERTENSION (PAH) AND OTHER DISORDERS
#897INDUCIBLE ANTI-SENSE REPRESSOR SWITCHES AND USES THEREOF
#898POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF
#899Antisense Oligonucleotides Targeting SARS-CoV-2
#900Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors